[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558739":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":22,"responsibleParty":44,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":74,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Turku University Hospital","OTHER_GOV",null,[9],{"name":10,"affiliation":5,"role":11},"Jukka Koffert, M.D., Ph.D","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Jukka Koffert, Ph.D.","CONTACT","+35823130000","jukka.koffert@varha.fi",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Achol Bhowmik, B.M.","+358449832346","achol.a.bhowmik@utu.fi",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Turku PET Centre","RECRUITING","Turku","Southwest Finland","20540","Finland","FI",{"type":32,"coordinates":33},"Point",[34,35],22.26869,60.45148,{"lat":35,"lon":34},[38,41],{"name":39,"role":15,"phone":16,"phoneExt":7,"email":40},"Pirjo Nuutila, M.D., Ph.D.","pirjo.nuutila@utu.fi",{"name":42,"role":15,"phone":16,"phoneExt":7,"email":43},"Kari Kalliokoski, Ph.D.","kari.kalliokoski@utu.fi",{"type":11,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Jukka Koffert","M.D., Ph.D., specialict in gastroenterology",[48],{"name":49,"class":50},"University of Turku","OTHER","100558739","investigation-of-vap-1-expression-and-tissue-blood-flow-by-pet-mri-in-patients-with-crohns-disease-100558739",false,"NCT06555042","Investigation of VAP-1 Expression and Tissue Blood Flow by PET-MRI in Patients With Crohn's Disease","Investigation of VAP-1 Expression and Tissue Blood Flow by Combined [68Ga]DOTA-Siglec-9 and [15O]H2O PET-MRI in Patients With Small Bowel's Crohn's Disease","VAP-PET","Inclusion Criteria:\n\n* Adults between age 18-70\n* Strong clinical suspicion of small bowel Crohn's disease\n* Able and willing to give written informed consent and to comply with the study protocol\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Previous capsule retention\n* X-ray investigations during preceding year\n* Patients with metallic implants such as an electronic pacemaker or an implanted infusion pump\n* Known stenosis of the GI-tract\n* Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation\n* Is unable or unwilling to comply with the study protocol for any reason","ALL","18 Years","70 Years",{"count":63,"type":64},20,"ESTIMATED","OBSERVATIONAL","This is an observational, single center, imaging study. The CD patients with active disease will be assessed by \\[68Ga\\]Ga-DOTA-Siglec-9 and \\[15O\\]H2O PET\u002FMRE. Patients with high clinical suspicion of small intestine's CD in outpatient gastroenterology clinic of Turku University Hospital will be recruited. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study.\n\n20 patients with high suspicion of active small bowels CD will be enrolled to being evaluated for potential participation in this study. In patients with diagnosed small bowels CD, PET-MRE will be repeated 3 months after the initial imaging (and based on clinical diagnostic started medication) to verify disease remission\u002Finadequacy of the treatment.\n\nAssessments for CD clinical disease activity will be performed at screening and \\[68Ga\\]Ga-DOTA-Siglec-9 and \\[15O\\]H2O PET\u002FMRE assessments will be performed within a month for each patient.\n\nAfter PET\u002FMRE all patients can be treated according to patients' needs with immunosuppressive drugs. Follow-up visits are organized at after PET\u002FMRE imaging at gastroenterology outpatient clinic.",[68,69,70,71,72,73],"Crohn Disease","Inflammatory Bowel Diseases","Crohn Disease of Small Intestine","Crohn Colitis","Crohn's Ileocolitis","Crohn Disease in Remission",[75,76,77,78,79],"Inflammatory Bowel Disease","Positron emission tomography","Crohn's disease","Vascular adhesion protein-1","Intestinal Perfusion","2024-08-14",{"date":82,"type":83},"2024-08-15","ACTUAL",{"date":85,"type":64},"2024-09",{"date":87,"type":64},"2026-06-06",{"name":5,"class":6},1]